Colín Lizalde Luis de Jesús
Departamento de Electrocardiografía y Electrofisiología Clínica, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1, Col Sección XVI, Tlapan, CP 14080, México, D. F. México.
Arch Cardiol Mex. 2003 Apr-Jun;73 Suppl 1:S26-30.
Hypertrophic cardiomyopathy is a relatively common genetic disorder with heterogeneity in mutations, forms of presentation, prognosis and treatment strategies. Hypertrophic cardiomyopathy is recognized as the most common cause of sudden cardiac death that occurs in young people, including athletes. The clinical diagnosis is complemented with the ecocardiographic study, in which an abnormal myocardial hypertrophy of the septum can be observed in the absence of a cardiac or systemic disease (arterial systemic hypertension, aortic stenosis). The annual sudden mortality rate is 1% and, in selected populations, it ranges between 3 and 6%. The therapeutic strategies depend on the different subsets of patients according to the morbidity and mortality, sudden cardiac death, obstructive symptoms, heart failure or atrial fibrillation and stroke. High risk patients for sudden death may effectively be treated with the automatic implantable cardioverter-defibrillator.
肥厚型心肌病是一种相对常见的遗传性疾病,在突变、表现形式、预后和治疗策略方面存在异质性。肥厚型心肌病被认为是年轻人(包括运动员)发生心源性猝死的最常见原因。临床诊断需辅以超声心动图检查,在此检查中可观察到在无心脏或全身性疾病(动脉性系统性高血压、主动脉瓣狭窄)的情况下室间隔出现异常心肌肥厚。年心源性猝死率为1%,在特定人群中,该比率在3%至6%之间。治疗策略取决于根据发病率和死亡率、心源性猝死、梗阻症状、心力衰竭或房颤及中风划分的不同患者亚组。猝死高危患者可通过植入式自动心脏除颤器得到有效治疗。